

0570  
0574

# 10



ENTERED

OIPE

## RAW SEQUENCE LISTING

DATE: 05/17/2002

PATENT APPLICATION: US/10/024,535A

TIME: 14:13:47

Input Set : A:\SEQ.10-024535.txt

Output Set: N:\CRF3\05172002\J024535A.raw

```

3 <110> APPLICANT: MARCEL et al.
5 <120> TITLE OF INVENTION: Therapeutic methods and compositions for the treatment
6   of impaired interpersonal and behavioral disorders
8 <130> FILE REFERENCE: P07479US01/BAS
10 <140> CURRENT APPLICATION NUMBER: US 10/024,535A
11 <141> CURRENT FILING DATE: 2001-12-21
13 <150> PRIOR APPLICATION NUMBER: PCT/EP00/06259
14 <151> PRIOR FILING DATE: 2000-06-22
16 <150> PRIOR APPLICATION NUMBER: US/140,563
17 <151> PRIOR FILING DATE: 1999-06-23
19 <160> NUMBER OF SEQ ID NOS: 10
21 <170> SOFTWARE: PatentIn Ver. 2.1
23 <210> SEQ ID NO: 1
24 <211> LENGTH: 5
25 <212> TYPE: PRT
26 <213> ORGANISM: Artificial Sequence
28 <220> FEATURE:
29 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve
therapeutic
30   effects in mammals.
32 <220> FEATURE:
33 <221> NAME/KEY: MISC_FEATURE
34 <222> LOCATION: (1)..(1)
35 <223> OTHER INFORMATION: Xaa is Glp
38 <400> SEQUENCE: 1
W--> 39 Xaa His Asn Pro Arg
40   1           5
43 <210> SEQ ID NO: 2
44 <211> LENGTH: 5
45 <212> TYPE: PRT
46 <213> ORGANISM: Artificial Sequence
48 <220> FEATURE:
49 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve
therapeutic
50   effects in mammals.
52 <400> SEQUENCE: 2
53 Gln His Asn Pro Arg
54   1           5
59 <210> SEQ ID NO: 3
60 <211> LENGTH: 4
61 <212> TYPE: PRT
62 <213> ORGANISM: Artificial Sequence
64 <220> FEATURE:
65 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve

```

therapeutic

66

effects in mammals.

## RAW SEQUENCE LISTING

DATE: 05/17/2002

PATENT APPLICATION: US/10/024,535A

TIME: 14:13:47

Input Set : A:\SEQ.10-024535.txt

Output Set: N:\CRF3\05172002\J024535A.raw

```

68 <220> FEATURE:
69 <221> NAME/KEY: MISC_FEATURE
70 <222> LOCATION: (1)..(1)
71 <223> OTHER INFORMATION: Xaa is Glp
74 <400> SEQUENCE: 3
W--> 75 Xaa His Asn Pro
76      1
78 <210> SEQ ID NO: 4
79 <211> LENGTH: 4
80 <212> TYPE: PRT
81 <213> ORGANISM: Artificial Sequence
83 <220> FEATURE:
84 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve
therapeutic
85      effects in mammals.
88 <400> SEQUENCE: 4
89 Gln His Asn Pro
90      1
92 <210> SEQ ID NO: 5
93 <211> LENGTH: 6
94 <212> TYPE: PRT
95 <213> ORGANISM: Artificial Sequence
97 <220> FEATURE:
98 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve
therapeutic
99      effects in mammals.
101 <400> SEQUENCE: 5
102 Arg Gln His Asn Pro Arg
103      1          5
105 <210> SEQ ID NO: 6
106 <211> LENGTH: 11
107 <212> TYPE: PRT
108 <213> ORGANISM: Artificial Sequence
110 <220> FEATURE:
111 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve
therapeutic
112      effects in mammals.
115 <400> SEQUENCE: 6
116 Val Arg Gly Pro Arg Gln His Asn Pro Arg
117      1          5          10
119 <210> SEQ ID NO: 7
120 <211> LENGTH: 5
121 <212> TYPE: PRT
122 <213> ORGANISM: Artificial Sequence
124 <220> FEATURE:
125 <223> OTHER INFORMATION: This is a peptide sequence that was designed to achieve
therapeutic
126      effects in mammals.
128 <400> SEQUENCE: 7
129 Gln His Asn Leu Arg
130      1          5
133 <210> SEQ ID NO: 8
134 <211> LENGTH: 6

```

## RAW SEQUENCE LISTING

DATE: 05/17/2002

PATENT APPLICATION: US/10/024,535A

TIME: 14:13:47

Input Set : A:\SEQ.10-024535.txt

Output Set: N:\CRF3\05172002\J024535A.raw

135 &lt;212&gt; TYPE: PRT

136 &lt;213&gt; ORGANISM: Artificial Sequence

138 &lt;220&gt; FEATURE:

139 &lt;223&gt; OTHER INFORMATION: This is a peptide sequence that was designed to achieve therapeutic

140 effects in mammals.

142 &lt;400&gt; SEQUENCE: 8

143 Arg Gln His Asn Leu Arg

144 1 5

147 &lt;210&gt; SEQ ID NO: 9

148 &lt;211&gt; LENGTH: 6

149 &lt;212&gt; TYPE: PRT

150 &lt;213&gt; ORGANISM: Artificial Sequence

152 &lt;220&gt; FEATURE:

153 &lt;223&gt; OTHER INFORMATION: This is a peptide sequence that was designed to achieve therapeutic

154 effects in mammals.

156 &lt;400&gt; SEQUENCE: 9

157 Gly Gln His Gly Pro Arg

158 1 5

160 &lt;210&gt; SEQ ID NO: 10

161 &lt;211&gt; LENGTH: 6

162 &lt;212&gt; TYPE: PRT

163 &lt;213&gt; ORGANISM: Artificial Sequence

165 &lt;220&gt; FEATURE:

166 &lt;223&gt; OTHER INFORMATION: This is a peptide sequence that was designed to achieve therapeutic

167 effects in mammals.

169 &lt;400&gt; SEQUENCE: 10

170 Gly Gln His Asp Pro Thr

171 1 5

RAW SEQUENCE LISTING ERROR SUMMARY      DATE: 05/17/2002  
PATENT APPLICATION: US/10/024,535A      TIME: 14:13:48

Input Set : A:\SEQ.10-024535.txt  
Output Set: N:\CRF3\05172002\J024535A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1

Seq#:3; Xaa Pos. 1

## VERIFICATION SUMMARY

DATE: 05/17/2002

PATENT APPLICATION: US/10/024,535A

TIME: 14:13:48

Input Set : A:\SEQ.10-024535.txt

Output Set: N:\CRF3\05172002\J024535A.raw

L:39 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0

L:75 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:0